Why is Senores Pharma. falling/rising?

As of 02-Sep, Senores Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 696.80, which reflects a decrease of 3.85 or 0.55%. The stock has underperformed its sector today by 0.48%, and while it remains above its 20-day, 50-day, 100-day, and 200-day moving averages, it is below its 5-day moving average. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 46.37% compared to the 5-day average. Over the past week, the stock has decreased by 1.18%, although it has shown a positive return of 4.54% over the past month and an impressive 22.48% year-to-date. Despite strong growth in net sales and operating profit, the stock's valuation appears expensive with a high Price to Book Value ratio, which may be contributing to the current price decline.
In the broader market context, the Sensex has decreased by 0.78% over the past week, indicating that while Senores Pharmaceuticals has underperformed relative to the benchmark, it has still managed to outperform it over the past month. However, the decline in institutional investor participation, which has seen a reduction in their stake by 0.65%, raises concerns about the stock's future performance, as these investors typically have more resources to analyze the company's fundamentals. This combination of high valuation, falling investor interest, and recent underperformance against both the sector and the benchmark suggests a cautious outlook for Senores Pharmaceuticals Ltd at this time.